Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
2.78
Industry P/E
--
Debt to Equity
--
ROE
-3.1 %
ROCE
-1567.83 %
Div. Yield
0 %
Book Value
780.55
EPS
-6143.73
CFO
$-28.89 Mln
EBITDA
$-33.20 Mln
Net Profit
$-33.76 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Dermata Therapeutics Inc (DRMA)
| -45.26 | -43.15 | -36.84 | 107.12 | -66.87 | 291.84 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Dermata Therapeutics Inc (DRMA)
| 119.88 | -90.68 | -76.49 | -96.52 | 0.00 | 0.00 | 0.00 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,135.98 | 20.78 | 23.13 | |
| 298.55 | 8,668.61 | 21.55 | 58.42 | |
| 27.22 | 9,559.25 | -- | -28.77 | |
| 106.73 | 10,030.35 | 30.81 | 14.16 |
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product... candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Address: 3525 Del Mar Heights Rd., San Diego, CA, United States, 92130 Read more
Founder, President, CEO & Chairman
Mr. Gerald T. Proehl
Founder, President, CEO & Chairman
Mr. Gerald T. Proehl
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Dermata Therapeutics Inc (DRMA) stood at $ 3,534 Mln as on 31-Dec-24
The share price of Dermata Therapeutics Inc (DRMA) is $0.74 (NASDAQ) as of 25-Apr-2025 16:06 EDT. Dermata Therapeutics Inc (DRMA) has given a return of -66.87% in the last 3 years.
Dermata Therapeutics Inc (DRMA) has a market capitalisation of $ 4 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Dermata Therapeutics Inc (DRMA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Dermata Therapeutics Inc (DRMA) and enter the required number of quantities and click on buy to purchase the shares of Dermata Therapeutics Inc (DRMA).
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Address: 3525 Del Mar Heights Rd., San Diego, CA, United States, 92130
The CEO & director of Mr. Gerald T. Proehl. is Dermata Therapeutics Inc (DRMA), and CFO & Sr. VP is Mr. Gerald T. Proehl.
There is no promoter pledging in Dermata Therapeutics Inc (DRMA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Dermata Therapeutics Inc (DRMA) | Ratios |
|---|---|
|
Return on equity(%)
|
-1567.83
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Dermata Therapeutics Inc (DRMA) was $0 Mln.
$-0.01
(
